HRCT CHEST FOR COVID-19

Hypro Diagnostics employed a non-probability consecutive sampling approach to enlist patients, ensuring a varied cohort. Eligibility criteria included a confirmed history of exposure to a known COVID-19 patient and the manifestation of any two among the following signs and symptoms: fever, cough, malaise, body aches, arthralgia, new-onset loss of taste and smell, or dyspnea, with oxygen saturation levels dipping below 85%. This methodical selection process was designed to capture a diverse spectrum of cases, contributing to a more nuanced comprehension of COVID-19 manifestations specific to Hypro Diagnostics.